1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Resverlogix Corp.

Resverlogix Corp.

RVX.TO
Resverlogix Corp.CA flagToronto Stock Exchange
0.10
CAD
+0.01
- -
31.70MMarket Cap
Resverlogix Corp.
RVX.TO
(Toronto Stock Exchange)

Recent

price

0.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.67
0.04
0.29
0.58
-0.69
-0.22
-0.2
-0.44
-0.42
-0.87
0.57
-0.1
-0.01
-0.06
-0.03
-0.03
-0.02
Basic EPS, GAAP
-0.45
-0.36
-0.38
-0.4
-0.18
-0.12
-0.22
-0.22
-0.19
-0.26
-0.09
-0.04
-0.02
-0.01
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.14
-2.45
-0.32
-0.83
-1.23
-1.31
-0.95
-1.34
-0.9
-1.34
-0.54
-0.48
-0.45
-0.48
-0.48
-0.5
-0.5
Book Value per Share
0.09
-0.1
0.02
-0.41
-0.8
-0.88
-0.58
-0.98
-0.62
-1.12
-0.32
-0.26
-0.24
-0.28
-0.3
-0.32
-0.32
Tangible Book Value per Share
41
51
65
74
79
85
101
105
138
188
208
240
254
270
280
285
290
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-936,940.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
Depreciation Expense
-27
2
19
43
-55
-18
-20
-46
-58
-163
118
-25
-4
-17
-8
-8
-6
Net Income, GAAP
- -
- -
- -
3.56
- -
- -
- -
- -
- -
- -
0.02
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-979,683.8
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
2
-6
1
-4
-5
-4
22
-64
-34
-76
-26
-14
-20
-26
-25
-42
-43
Working Capital
- -
- -
- -
27
26
45
48
- -
- -
- -
1
- -
- -
- -
8
- -
- -
LT Debt
4
-4
3
-30
-63
-74
-56
-102
-84
-208
-64
-60
-59
-74
-82
-89
-90
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-1.64
- -
-161.22
- -
- -
- -
- -
- -
- -
-71.84
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
20
21
22
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
287
288
316
Market Capitalization
20
21
22

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
2
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
42
44
44
Payables & Accruals
21
23
22
ST Debt
20
21
22
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.46%
7.32%
8.84%
Free Cash Flow
7.48%
-16.9%
-0.02%
Net Income, GAAP
27.95%
20.93%
1.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.02
-0.02
- -
-0.03
2025
-0.02
-0.01
- -
- -
-0.03
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Entropy Neurodynamics Limited (ENP.AX)
ABIONYX Pharma S.A. (ABNX.PA)
Feng Chi Biotech Corp. (6744.TWO)
First Tracks Biotherapeutics Inc (TRAX)
Ovoca Bio plc (OVB.L)
Cellectis S.A. (ALCLS.PA)
Business
Resverlogix Corp. is a Calgary, Alberta-based late-stage clinical biotechnology company founded in 2001 that develops epigenetic therapies to treat patients with chronic diseases by regulating disease-causing gene expression through inhibition of bromodomain and extra-terminal (BET) proteins. The company's lead product candidate is apabetalone (RVX-208), a selective BET inhibitor targeting the second bromodomain (BD2) for indications including high-risk cardiovascular disease in patients with type 2 diabetes mellitus and low high-density lipoprotein levels as evaluated in the global Phase 3 BETonMACE clinical trial, post-COVID-19 conditions, pulmonary arterial hypertension, end-stage renal disease, chronic kidney disease, neurodegenerative diseases, Fabry disease, peripheral artery disease, and other orphan indications such as facioscapulohumeral muscular dystrophy. It maintains a partnership with EVERSANA to support commercialization of apabetalone for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States; Shenzhen Hepalink Pharmaceutical Group Co., Ltd., its largest shareholder, holds a US$6.0 million secured debenture extended in May 2024 for two years to May 13, 2026, with conversion privileges eliminated and interest rate increased to 18% per annum. Recent developments include the appointment of Bradley Glass, General Counsel of Hepalink USA, Inc., to the board of directors in November 2025; shareholder approval of the board at the June 2025 annual meeting; a presentation on apabetalone's anti-inflammatory and anti-fibrotic effects in cardiac fibroblasts at the European Society of Cardiology Congress 2024; and ongoing advancements in Zenith Capital funding during 2025. Operations are primarily in Canada with a U.S. office in San Francisco, California, and the company trades on the Toronto Stock Exchange under the symbol RVX.TO.

Company News

APIChatGPT